Welcome to the second episode of PBS Update, a new podcast series from Oncology Network designed to keep healthcare professionals up to date with key changes to the Australian Pharmaceutical Benefits Scheme (PBS).

Join our Hosts Professor Craig Underhill and Rachael Babin to discuss the April 2026 PBS update, including a new listing for repotrectinib and new indications for durvalumab and pembrolizumab.

For links to resources mentioned in the Podcast, please see below.

Physicians, don’t forget you can claim CME points for listening to the show!

With thanks to our Editor, Graham Knowles.